Zhixue Fu,Kun Yang,Xu Yang et al.
Zhixue Fu et al.
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial [0.03%]
依立替康联合S-1与单用S-1治疗复发或转移性食管癌患者的前瞻性、随机、多中心、开放标签的III期临床研究(ESWN 01)
Jing Huang,Binghe Xu,Ying Liu et al.
Jing Huang et al.
Background: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been esta...
The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study [0.03%]
鼻咽癌患者残留颈淋巴结病灶的血浆EB病毒DNA诊断及预后价值：回顾性研究
Sai-Lan Liu,Xue-Song Sun,Xiao-Yun Li et al.
Sai-Lan Liu et al.
Background: Currently, the diagnosis and treatment of nasopharyngeal carcinoma (NPC) patients with residual cervical lymphadenopathy following radical radiotherapy with or without chemotherapy are challenging. We investig...
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options [0.03%]
黏液性结直肠腺癌的临床病理和治疗选择
Cong Luo,Shuyi Cen,Guojun Ding et al.
Cong Luo et al.
Mucinous colorectal adenocarcinoma is a distinct subtype of colorectal cancer (CRC) characterized by the presence of abundant extracellular mucin which accounts for at least 50% of the tumor volume. Mucinous colorectal adenocarcinoma is fou...
Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy [0.03%]
向精准医疗前进：液态活检中5-羟甲基胞嘧啶癌症生物标志物研究进展
Chang Zeng,Emily Kunce Stroup,Zhou Zhang et al.
Chang Zeng et al.
Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and prognosis have great potential to improve patient survival and are the key to precision medicine. The advent of next-generation sequencing technologies e...
Recent trends from the results of clinical trials on gastric cancer surgery [0.03%]
近期胃癌外科手术临床试验结果的新趋势分析
Takashi Kiyokawa,Takeo Fukagawa
Takashi Kiyokawa
The Japan Clinical Oncology Group has recently conducted large scale clinical trials with findings that have revealed pivotal strategies for the treatment of resectable gastric cancer surgery. These findings include the fact that D3 lymphad...
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer [0.03%]
中国临床肿瘤学会胃癌诊疗指南
Feng-Hua Wang,Lin Shen,Jin Li et al.
Feng-Hua Wang et al.
China is one of the countries with the highest incidence of gastric cancer. There are differences in epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selection bet...
Practice Guideline
Cancer communications (London, England). 2019 Mar 18;39(1):10. DOI:10.1186/s40880-019-0349-9 2019
Disrupting redox stabilizer: a novel therapeutic strategy for colorectal cancer [0.03%]
扰乱氧化还原稳定剂：一种治疗结直肠癌的新策略
Dunyaporn Trachootham,Watcharapol Khoonin
Dunyaporn Trachootham
Skull bone tumor: a review of clinicopathological and neuroimaging characteristics of 426 cases at a single center [0.03%]
颅骨肿瘤的临床病理及神经影像特征分析（426例报告）
Hailong Liu,Xueying Zhang,Mingshan Zhang et al.
Hailong Liu et al.
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations [0.03%]
鉴定EGFR敏感突变型晚期非小细胞肺癌患者原发性对EGFR-TKI耐药的基因改变
Fang Wang,Xia-Yao Diao,Xiao Zhang et al.
Fang Wang et al.
Background: Identification of activated epidermal growth factor receptor (EGFR) mutations and application of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have greatly changed the therapeutic strategies of non-small-cell lu...